A recent Device study reported the effectiveness of an ingestible vitals-monitoring pill (VM pill) to monitor vital signs, including heart and respiratory rate based on a human trial.
Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional